Get to know our clinical trials
Ensayo de Epcoritamab en combinación con antineoplásicos en pacientes con linfoma no Hodgkin
THE PURPOSE OF THIS STUDY IS TO EVALUATE A DRUG CALLED EPCORITAMAB IN COMBINATION WITH OTHER DRUGS USED TO TREAT NON-HODGKIN LYMPHOMA (NHL). EPCORITAMAB MAY WORK BETTER WHEN COMBINED WITH OTHER DRUGS THAT TREAT CANCER IN DIFFERENT WAYS.
Technical Summary
- PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF EPCORITAMAB IN COMBINATION WITH ANTINEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA. IMMUNOTHERAPY
- Code EudraCT: 2023-505347-38
- Protocol number: M22-132
- Promoter: Abbvie farmacéutica
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Trial of Epcoritamab in combination with antineoplastic agents in patients with non-Hodgkin lymphoma
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.